Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.

Abstract

BACKGROUND Cariprazine is a novel antipsychotic agent recently approved for treating schizophrenia and bipolar mania in the USA. The sample sizes of published randomized controlled trials (RCTs) of the drug are small; previous meta-analyses included few RCTs and did not specifically investigate the tolerability/safety profile of cariprazine. OBJECTIVE Our… (More)

Topics

Cite this paper

@article{Lao2016TolerabilityAS, title={Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.}, author={Kim S J Lao and Ying He and Ian Chi Kei Wong and Frank M C Besag and Esther W Chan}, journal={CNS drugs}, year={2016}, volume={30 11}, pages={1043-1054} }